Topiramate for Childhood Obesity
(PHARMATOP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the effectiveness of the drug topiramate for weight loss in teenagers with severe obesity. Researchers aim to understand how different doses affect weight and related outcomes, using pharmacometrics to tailor treatment to individual needs. The trial targets teens with a significantly higher-than-normal body mass index (BMI) who a specialist has identified as suitable for topiramate. As an Early Phase 1 trial, this research focuses on understanding the treatment's effects in people, offering participants a chance to contribute to groundbreaking insights.
Will I have to stop taking my current medications?
The trial requires that you have not used certain anti-obesity medications or medications associated with weight gain in the past 6 months unless you've been on a stable dose for at least 6 months. If you're taking long-acting stimulant medications, you must also have been on a stable dose for at least 6 months. Check with the trial team to see if your specific medications are affected.
Is there any evidence suggesting that this treatment is likely to be safe for humans?
Research has shown that topiramate has treated seizures in children as young as two for many years, indicating some level of safety for young patients. However, topiramate can cause side effects. Some studies have highlighted possible issues like slower growth in height and weight in children. Additionally, topiramate might raise body temperature and decrease sweating, potentially leading to dehydration, especially in kids. While often prescribed for weight loss in young people with severe obesity, these risks should be considered when evaluating participation in a clinical trial.12345
Why do researchers think this study treatment might be promising?
Unlike the standard treatments for childhood obesity, which often include lifestyle changes, dietary adjustments, and medications like metformin, topiramate offers a unique approach. Originally an anticonvulsant medication, topiramate works by targeting the brain's neurotransmitters to help reduce appetite and manage weight. Researchers are excited about topiramate because it has the potential to provide an effective pharmacological option that directly addresses the neurological components of obesity, potentially leading to better long-term weight management in children.
What evidence suggests that topiramate might be an effective treatment for childhood obesity?
Research has shown that topiramate, the investigational treatment in this trial, combined with lifestyle changes, can significantly lower body mass index (BMI) in teenagers. Studies have found that this combination can lead to an average BMI reduction of 4–6%. Although topiramate is primarily approved for treating epilepsy and migraines, it is also used for weight loss in adults, often with another drug called phentermine. Topiramate seems to work by altering brain chemicals that control appetite. While results can vary among individuals, these findings suggest that topiramate could help manage weight in young people with severe obesity.36789
Who Is on the Research Team?
Eric Bomberg, MD
Principal Investigator
University of Minnesota
Are You a Good Fit for This Trial?
This trial is for youth aged 12 to under 18 with severe obesity, defined as a BMI at or above certain thresholds. Candidates must be considered appropriate for topiramate treatment by an obesity specialist and have no history of metabolic surgery, significant thyroid disorders, major psychiatric disorders, eating disorders, recent suicide attempts or use of certain weight-related medications.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive topiramate with dose escalation from 25 mg to 75 mg daily over 3.5 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Topiramate
Trial Overview
The PHARMATOP study tests how the drug topiramate affects weight loss in young people with severe obesity. It uses pharmacometrics to understand the relationship between dosage and individual responses to optimize dosing based on patient-specific characteristics.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Individuals will receive 75 mg of topiramate daily. The dose will start at 25 mg daily for the first week. The second week participants will receive 50 mg daily. Starting at week 3 participants will take 75 mg daily.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Minnesota
Lead Sponsor
Published Research Related to This Trial
Citations
Medications for the treatment of obesity in adolescents - PMC
Topiramate is currently FDA approved for the treatment of epilepsy (⩾2 years old), migraines (⩾12 years old), and obesity, in combination with phentermine (⩾18 ...
Topiramate for Weight Reduction in Adolescents with ...
The results demonstrate that topiramate with concurrent lifestyle modification is associated with clinically-significant BMI reduction, on the order of 4–6% ...
Paired Anti-Obesity Drugs May Help Teens Shed More ...
"Initial efficacy data support greater reduction in BMI with phentermine and topiramate versus placebo at 12 weeks." Patients in the study ...
Adjunctive Anti-Obesity Pharmacotherapy in Adolescents ...
2) Phentermine and Topiramate were paired to theoretically reduce/neutralize the side effects seen with either medication alone, and additively or ...
Review Article Emerging pharmacotherapies for obesity
Completed phase 2 trials on incretin-based therapies showed a mean percent weight loss of 7.4% to 24.2%. Almost half of the drugs undergoing phase 2 trials are ...
qudexy® xr - accessdata.fda.gov
The safety data presented below are from 249 patients ... The safety and effectiveness of QUDEXY XR in pediatric patients is based on controlled trials.
Topiramate (oral route) - Side effects & dosage
Safety and efficacy have not been established. Appropriate studies have not been performed on the relationship of age to the effects of Trokendi ...
Topiramate Clinical Data | Trokendi XR® HCP
Immediate-release topiramate monotherapy demonstrated negative effects on growth (height and weight) among pediatric patients in a one-year active controlled ...
Topiramate: Uses, Dosage, Side Effects, Warnings
Topiramate can increase body temperature and decrease sweating, leading to life-threatening dehydration (especially in children). Avoid the use ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.